ICML 2019 | Cami-T in R/R cHL: analysis of clinical determinants of safety and efficacy

Alexandre Hirayama

Alexandre Hirayama, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the analysis of the clinical determinants for the safety and effiacy of camidanlumab tesirine (Cami-T; ADCT-301) for relapsed/refractory classical Hodgkin lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video  
Similar topics
Related videos
Venetoclax monotherapy for relapsed/refractory Waldenström’s macroglobulinemia
Jorge Castillo
Waldenström's PFS unaffected by ibrutinib dose reduction, for now
Jorge Castillo
Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
Saar Gill
Waldenström’s macroglobulinemia: a link between institution visited and survival
Stephen Ansell
1:42
New therapeutic directions in CTCL
Pierluigi Porcu
Hodgkin Lymphoma, Lymphoma
Antibodies, Camidanlumab tesirine
ICML 2019
Interview
More from Alexandre Hirayama
Durable responses after CD19 CAR-T plus ibrutinib in CLL
Recent publication on the impact of response to lymphodepletion on PFS in NHL
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals